Better Health for All

Argenx's core business is dedicated to improving the lives of people with severe autoimmune and rare diseases, with an FDA-approved treatment (VYVGART) and a pipeline of investigational medicines, indicating an exceptional health impact.

VYVGART and VYVGART Hytrulo are the prescribed FDA-approved biologic treatments for adults with anti-AChR antibody positive gMG. In 2024, the company reported no FDA Safety Notices, product recalls, or GMP violations, and no data breaches involving sensitive patient information, demonstrating an outstanding safety record and data responsibility. However, Vyvgart is listed under additional monitoring by the European Medicines Agency. For price accessibility, the company's largest product list price increased by 2% and net price by 1% in 2024. Wholesale Acquisition Costs (WAC) for VYVGART are $6,190.38 per 400 mg vial and VYVGART Hytrulo is $16,088.46 per 1,008 mg vial. A $0 co-pay program for eligible commercially insured patients has a maximum benefit of $25,000 per year, and over 95% of commercially insured patients have coverage. The company participates in Medicare, Medicaid, and 340B programs. Argenx provides Pre-Approval Access (PAA) to 70 patients in 2024 for investigational medicines for life-threatening conditions, with inquiries addressed within 5 business days. The company collaborates with patient advocacy groups for rare diseases and marginalized communities and has a podcast series for underserved patients. Risk transparency includes communicating significant safety findings and requiring favorable risk-benefit assessments for pre-approval access. The company also engages in disease education through websites and educational materials.

Fair Money & Economic Opportunity

Argenx SE is a global immunology company focused on developing antibody-based medicines, not a financial services provider.

The provided articles discuss patient assistance programs and the challenges of drug reimbursement and pricing, but they do not contain any information related to lending, deposit services, or financial products for consumers. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are scored as 0, indicating they are not applicable to the company's core business model as defined by the rubric.

Kind to Animals

Argenx audits 100% of its third-party collaborators involved in research activities, reviewing external certifications like AAALAC International or performing due diligence for uncertified partners.

The company has an Animal Welfare Policy, effective June 18, 2024, which commits to the 3R principles (Replace, Reduce, Refine) and requires high-level sign-off for exceptions. However, it also states that research using living animals remains essential and cannot be fully replaced in the foreseeable future. Argenx uses alternative methods like organ-chip technology for screening drug candidates and in vitro/ex-vivo experiments where possible, but these assays cover early-stage toxicity screens and are rarely used for complex endpoints. The company encourages all third parties conducting animal research to be certified by AAALAC International and reviews these certifications, but the evidence indicates that approximately 25% of operations hold humane certification. Argenx engages with the animal welfare science community and collaborates with organ-chip makers like Hesperos, but the extent of this collaboration is not quantified beyond being a member of an industry consortium with minimal contributions.

No War, No Weapons

The company is an immunology firm focused on developing antibody-based medicines, and its core business is not related to arms manufacturing, military contracts, or conflict facilitation. There is no evidence of revenue from arms or defense contracts, R&D in dual-use technologies, or any involvement in controversial weapons.

The company does not generate revenues in Russia, and its clinical trial activities in Russia are explicitly authorized by U.S. General Licenses 6C and 6D for medical research. There is no evidence of lobbying related to arms control, procurement from conflict-affected areas, or investment in peacebuilding initiatives. The company's operations do not require war-risk audits, conflict-zone procurement, or specific ethical red lines related to weapons. The company states a commitment to respecting human rights and complying with international labor standards, including prohibiting child and forced labor, and upholding freedom of association and non-discrimination. It also undertakes due diligence for business arrangements, including reviewing third parties' Codes of Business Conduct.

Planet-Friendly Business

In 2024, the company reported total Scope 1, 2, and 3 greenhouse gas emissions of 231,769 tCO₂e.

All of its operational energy consumption, totaling 17,989,405 kWh, was sourced from fossil fuels, with 0 kWh from renewable sources. The company's waste management efforts in 2024 resulted in 21.25 tons of waste diverted from disposal out of a total of 38.60 tons, representing a 55% diversion rate. Regarding EU Taxonomy alignment for 2024, 5.8% of its capital expenditure was aligned. The company conducted a comprehensive climate risk assessment in 2024, utilizing IPCC scenarios (SSP1, SSP2, SSP5) for physical risks and IEA scenarios (STEPS, APS, NZE) for transition risks across three time horizons and 43 locations.

Safe & Smart Tech

The company experienced low-risk external data breaches involving vendors in 2023 and 2024, which had limited impact and did not require disclosure to authorities.

It provides routine annual data security, privacy, and phishing awareness training to all employees and contractors, with 98.83% of global employees completing GDPR training in 2023. The company uses encryption for sensitive personal data stored on servers and has an Information Security Policy that includes encryption. It has controls for vendor-owned assets processing personal information and states that personal data not relevant for a report is deleted without undue delay. The company adheres to GDPR, HIPAA, and APPI standards, and its ISMS aligns with ISO 27001. It conducts audits and tests of its information systems and has processes to identify and manage information security risks. Privacy considerations are integrated into product development through impact assessments (CSIAs and DPIAs). Users, specifically Healthcare Professionals, have rights to inquire, opt out, review, correct, restrict, object to processing, and delete their personal data. The company maintains appropriate security procedures and practices to protect data, including technical and organizational measures to restrict access.